PuSH - Publication Server of Helmholtz Zentrum München

Dobiasch, S.* ; Kampfer, S.* ; Burkhardt, R. ; Schilling, D. ; Schmid, T.E. ; Wilkens, J.J. ; Combs, S.E.

BioXmark for high-precision radiotherapy in an orthotopic pancreatic tumor mouse model: Experiences with a liquid fiducial marker.

BioXmark für die Hochpräzisionsstrahlentherapie im orthotopen Pankreastumor-Mausmodell: Erfahrungen mit einem liquiden Marker.

Strahlenther. Onkol. 193, 1039-1047 (2017)
DOI Order publishers version
Open Access Green as soon as Postprint is submitted to ZB.
Background and purpose: High-precision radiotherapy (RT) requires precise positioning, particularly with high single doses. Fiducial markers in combination with onboard imaging are excellent tools to support this. The purpose of this study is to establish a pancreatic cancer mouse model for high-precision image-guided RT (IGRT) using the liquid fiducial marker BioXmark (Nanovi, Kongens Lyngby, Denmark). Methods: In an animal-based cancer model, different volumes of BioXmark (10–50 µl), application forms, and imaging modalities—cone-beam computer tomography (CBCT) incorporated in either the Small Animal Radiation Research Platform (SARRP) or the small-animal micro-CT Scanner (SkyScan; Bruker, Brussels, Belgium)—as well as subsequent RT with the SARRP system were analyzed to derive recommendations for BioXmark. Results: Even small volumes (10 µl) of BioXmark could be detected by CBCT (SARRP and Skyscan). Larger volumes (50 µl) led to hardening artefacts. The position of BioXmark was monitored at least weekly by CBCT and was stable over 4 months. BioXmark was shown to be well tolerated; no changes in physical condition or toxic side effects were observed in comparison to control mice. BioXmark enabled an exact fusion with the original treatment plan with less hardening artefacts, and minimized the application o f contrast agent for fractionated RT. Conclusion: An orthotopic pancreatic tumor mouse model was established for high-precision IGRT using a fiducial marker. BioXmark was successfully tested and provides the perfect basis for improved imaging in high-precision RT. BioXmark enables a unique application method and optimal targeted precision in fractionated RT. Therefore, preclinical trials evaluating novel fractionation regimens and/or combination treatment with high-end RT can be performed.
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Keywords Cone-beam Computed Tomography ; Dose Fractionation ; Models, Animal ; Pancreatic Neoplasms ; Radiotherapy, Image-guided; Radiation-therapy; Neoadjuvant Chemoradiation; Cancer; Ultrasound; Placement; Motion
ISSN (print) / ISBN 0179-7158
e-ISSN 1439-099X
Quellenangaben Volume: 193, Issue: 12, Pages: 1039-1047 Article Number: , Supplement: ,
Publisher Urban & Vogel
Publishing Place Heidelberg
Reviewing status Peer reviewed